Magdalena Staniszewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Magdalena Staniszewska has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Ken Herrmann
Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, DKTK
5 shared publications - Janette Iking
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany
4 shared publications - Katharina Lückerath
Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen
4 shared publications - Pedro Fragoso Costa
Department of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Essen, Germany
4 shared publications - Wolfgang Peter Fendler
Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany
4 shared publications - Jasmin M. Klose
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany
3 shared publications
Latest Publications
- Open Access
- 28 February 2026
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 11 (1)
Ensuring enantiomeric consistency in FAPI radiopharmaceuticals: comparative analysis of (S)- and (S/R)-FAPI-46/-74 confirms pharmacological equivalence
Background: Enantiomeric composition may impact binding and potentially performance of a drug product but is not routinely tested and minimum acceptance criteria are not always established. Some batches of the precursors FAPI-46 and FAPI-74 used clinically contain a mixture of ( S )- and ( R )-enantiomers. This study investigates the in vitro pharmacodynamic characteristics of different enantiomeric compositions of FAP-targeting radioligands FAPI-46 and FAPI-74 and in vivo pharmacokinetics of FAPI-46 in naïve mice. Results: ( S )-, ( R )-, and ( S/R )-enantiomers of radiolabeled FAPI-46 and FAPI-74 were evaluated for stability in human serum, binding affinity, internalization, retention, and selectivity using HT1080-hFAP cells and HEK293-hCD26 cells. All enantiomeric compositions showed high stability in human serum with minimal serum protein adhesion. ( S )- and ( S/R )-enantiomers exhibited comparable binding, internalization, and retention characteristics. High selectivity for FAP over CD26/DPP4 was maintained. ( R )-enantiomers showed no specific binding to FAP. Additionally, the same enantiomers of 68 Ga-labeled FAPI-46 were evaluated by dynamic positron emission tomography (PET) imaging (0–60 min post-injection) and ex vivo organ biodistribution in naïve BALB/c mice (10, 30, and 60 min, or 4 h post-injection) to compare their pharmacokinetic profiles. PET imaging revealed nearly identical time-activity curves for the enantiomers of [ 68 Ga] Ga-FAPI-46, indicating similar whole-body distribution within 1 h post-injection, with rapid renal clearance and minimal muscle uptake. Ex vivo organ biodistribution confirmed comparable pharmacokinetic profiles between enantiomers, with no significant differences in tissue distribution. Conclusion: These findings provide important validation that current clinical ( S/R )-mixtures of FAPI-46/-74 exhibit pharmacokinetic and pharmacodynamic behavior comparable to pure ( S )-enantiomers, supporting regulatory confidence and cross-trial reproducibility in the global FAPI-46/-74 imaging landscape.
- 28 February 2026
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 11 (1)
Open AccessEnsuring enantiomeric consistency in FAPI radiopharmaceuticals: comparative analysis of (S)- and (S/R)-FAPI-46/-74 confirms pharmacological equivalence
Background: Enantiomeric composition may impact binding and potentially performance of a drug product but is not routinely tested and minimum acceptance criteria are not always established. Some batches of the precursors FAPI-46 and FAPI-74 used clinically contain a mixture of ( S )- and ( R )-enantiomers. This study investigates the in vitro pharmacodynamic characteristics of different enantiomeric compositions of FAP-targeting radioligands FAPI-46 and FAPI-74 and in vivo pharmacokinetics of FAPI-46 in naïve mice. Results: ( S )-, ( R )-, and ( S/R )-enantiomers of radiolabeled FAPI-46 and FAPI-74 were evaluated for stability in human serum, binding affinity, internalization, retention, and selectivity using HT1080-hFAP cells and HEK293-hCD26 cells. All enantiomeric compositions showed high stability in human serum with minimal serum protein adhesion. ( S )- and ( S/R )-enantiomers exhibited comparable binding, internalization, and retention characteristics. High selectivity for FAP over CD26/DPP4 was maintained. ( R )-enantiomers showed no specific binding to FAP. Additionally, the same enantiomers of 68 Ga-labeled FAPI-46 were evaluated by dynamic positron emission tomography (PET) imaging (0–60 min post-injection) and ex vivo organ biodistribution in naïve BALB/c mice (10, 30, and 60 min, or 4 h post-injection) to compare their pharmacokinetic profiles. PET imaging revealed nearly identical time-activity curves for the enantiomers of [ 68 Ga] Ga-FAPI-46, indicating similar whole-body distribution within 1 h post-injection, with rapid renal clearance and minimal muscle uptake. Ex vivo organ biodistribution confirmed comparable pharmacokinetic profiles between enantiomers, with no significant differences in tissue distribution. Conclusion: These findings provide important validation that current clinical ( S/R )-mixtures of FAPI-46/-74 exhibit pharmacokinetic and pharmacodynamic behavior comparable to pure ( S )-enantiomers, supporting regulatory confidence and cross-trial reproducibility in the global FAPI-46/-74 imaging landscape.
- Open Access
- 31 May 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (6) , 824
Demonstration of the Early Cardiac Bioavailability of a Non-Specific Cell-Targeted Peptide Using Radionuclide-Based Imaging In Vivo
The cardiac bioavailability of peptide drugs that inhibit harmful intracellular protein–protein interactions in cardiovascular diseases remains a challenging task in drug development. This study investigates whether a non-specific cell-targeted peptide drug is available in a timely manner at its intended biological destination, the heart, using a combined stepwise nuclear molecular imaging approach. An octapeptide (heart8P) was covalently coupled with the trans-activator of transcription (TAT) protein transduction domain residues 48–59 of human immunodeficiency virus-1 (TAT-heart8P) for efficient internalization into mammalian cells. The pharmacokinetics of TAT-heart8P were evaluated in dogs and rats. The cellular internalization of TAT-heart8P-Cy(5.5) was examined on cardiomyocytes. The real-time cardiac delivery of 68Ga-NODAGA-TAT-heart8P was tested in mice under physiological and pathological conditions. Pharmacokinetic studies of TAT-heart8P in dogs and rats revealed a fast blood clearance, high tissue distribution, and high extraction by the liver. TAT-heart-8P-Cy(5.5) was rapidly internalized in mouse and human cardiomyocytes. Correspondingly, organ uptake of hydrophilic 68Ga-NODAGA-TAT-heart8P occurred rapidly after injection with an initial cardiac bioavailability already 10 min post-injection. The saturable cardiac uptake was revailed by the pre-injection of the unlabeled compound. The cardiac uptake of 68Ga-NODAGA-TAT-heart8P did not change in a model of cell membrane toxicity. This study provides a sequential stepwise workflow to evaluate the cardiac delivery of a hydrophilic, non-specific cell-targeting peptide. 68Ga-NODAGA-TAT-heart8P showed rapid accumulation in the target tissue early after injection. The implementation of PET/CT radionuclide-based imaging methodology as a means to assess effective and temporal cardiac uptake represents a useful and critical application in drug development and pharmacological research and can be extended to the evaluation of comparable drug candidates.
- 31 May 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (6) , 824
Open AccessDemonstration of the Early Cardiac Bioavailability of a Non-Specific Cell-Targeted Peptide Using Radionuclide-Based Imaging In Vivo
The cardiac bioavailability of peptide drugs that inhibit harmful intracellular protein–protein interactions in cardiovascular diseases remains a challenging task in drug development. This study investigates whether a non-specific cell-targeted peptide drug is available in a timely manner at its intended biological destination, the heart, using a combined stepwise nuclear molecular imaging approach. An octapeptide (heart8P) was covalently coupled with the trans-activator of transcription (TAT) protein transduction domain residues 48–59 of human immunodeficiency virus-1 (TAT-heart8P) for efficient internalization into mammalian cells. The pharmacokinetics of TAT-heart8P were evaluated in dogs and rats. The cellular internalization of TAT-heart8P-Cy(5.5) was examined on cardiomyocytes. The real-time cardiac delivery of 68Ga-NODAGA-TAT-heart8P was tested in mice under physiological and pathological conditions. Pharmacokinetic studies of TAT-heart8P in dogs and rats revealed a fast blood clearance, high tissue distribution, and high extraction by the liver. TAT-heart-8P-Cy(5.5) was rapidly internalized in mouse and human cardiomyocytes. Correspondingly, organ uptake of hydrophilic 68Ga-NODAGA-TAT-heart8P occurred rapidly after injection with an initial cardiac bioavailability already 10 min post-injection. The saturable cardiac uptake was revailed by the pre-injection of the unlabeled compound. The cardiac uptake of 68Ga-NODAGA-TAT-heart8P did not change in a model of cell membrane toxicity. This study provides a sequential stepwise workflow to evaluate the cardiac delivery of a hydrophilic, non-specific cell-targeting peptide. 68Ga-NODAGA-TAT-heart8P showed rapid accumulation in the target tissue early after injection. The implementation of PET/CT radionuclide-based imaging methodology as a means to assess effective and temporal cardiac uptake represents a useful and critical application in drug development and pharmacological research and can be extended to the evaluation of comparable drug candidates.
- 6 January 2022
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 63 (9) , 1357-1363
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
Introduction: The NETTER-1, VISION, and TheraP trials prove efficacy of repeat intravenous (i.v.) application of small radioligands. Application by subcutaneous (s.c.), intraperitoneal (i.p.), or oral (p.o.) access are important alternatives and may yield comparable or favorable organ and tumor radioligand uptake. Here, we assess organ and tumor biodistribution for various radioligand application routes in healthy mice and models of somatostatin receptor (SSTR)-, prostate-specific membrane antigen (PSMA)-, and fibroblast activation protein (FAP)- expressing cancer. Methods: Healthy and tumor-bearing male C57BL/6 or NOD SCID Gamma mice, respectively, were applied with a mean of 6.0±0.5 MBq 68Ga DOTATOC (RM1-SSTR allograft), 5.3±0.3 MBq 68Ga-PSMA11 (RM1-PSMA allograft) or 4.8±0.2 MBq 68Ga-FAPI46 (HT1080 FAP xenograft) i.v., i.p., s.c. or p.o.. In vivo positron emission tomography and ex vivo biodistribution in tumor, organs, and at the injection site were assessed up to 5h post injection (p.i.). Healthy mice were monitored for up to 7 days after the last scan for signs of stress or adverse reactions. Results: After i.v., i.p. and s.c. radioligand administration, average residual activity at the injection site was P = 0.0197) / 6.5±1.3%IA/g (P = 0.0827) versus 2.9±0.3%IA/g; PSMA: 3.4±0.8%IA/g (P = 0.9954) / 3.9±0.8%IA/g (P = 0.8343) versus 3.3±0.7%IA/g and FAP: 1.1±0.1%IA/g (P = 0.9805) / 1.1±0.1%IA/g (P = 0.7446) versus 1.0±0.2%IA/g. Conclusion: In healthy mice, biodistribution of small theranostic ligands following i.p. or s.c. application is nearly equivalent compared to i.v. injection. S.c. administration resulted in highest absolute SSTR tumor and tumor-to-organ uptake as compared to the i.v. route, warranting further clinical assessment.
- 6 January 2022
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 63 (9) , 1357-1363
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
Introduction: The NETTER-1, VISION, and TheraP trials prove efficacy of repeat intravenous (i.v.) application of small radioligands. Application by subcutaneous (s.c.), intraperitoneal (i.p.), or oral (p.o.) access are important alternatives and may yield comparable or favorable organ and tumor radioligand uptake. Here, we assess organ and tumor biodistribution for various radioligand application routes in healthy mice and models of somatostatin receptor (SSTR)-, prostate-specific membrane antigen (PSMA)-, and fibroblast activation protein (FAP)- expressing cancer. Methods: Healthy and tumor-bearing male C57BL/6 or NOD SCID Gamma mice, respectively, were applied with a mean of 6.0±0.5 MBq 68Ga DOTATOC (RM1-SSTR allograft), 5.3±0.3 MBq 68Ga-PSMA11 (RM1-PSMA allograft) or 4.8±0.2 MBq 68Ga-FAPI46 (HT1080 FAP xenograft) i.v., i.p., s.c. or p.o.. In vivo positron emission tomography and ex vivo biodistribution in tumor, organs, and at the injection site were assessed up to 5h post injection (p.i.). Healthy mice were monitored for up to 7 days after the last scan for signs of stress or adverse reactions. Results: After i.v., i.p. and s.c. radioligand administration, average residual activity at the injection site was P = 0.0197) / 6.5±1.3%IA/g (P = 0.0827) versus 2.9±0.3%IA/g; PSMA: 3.4±0.8%IA/g (P = 0.9954) / 3.9±0.8%IA/g (P = 0.8343) versus 3.3±0.7%IA/g and FAP: 1.1±0.1%IA/g (P = 0.9805) / 1.1±0.1%IA/g (P = 0.7446) versus 1.0±0.2%IA/g. Conclusion: In healthy mice, biodistribution of small theranostic ligands following i.p. or s.c. application is nearly equivalent compared to i.v. injection. S.c. administration resulted in highest absolute SSTR tumor and tumor-to-organ uptake as compared to the i.v. route, warranting further clinical assessment.
- Open Access
- 11 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (14) , 7431
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutamide on PSMA expression. Assessment of PSMA and androgen receptor (AR) expression on the human PC cell lines 22Rv1, C4-2, and LNCaP by immunohistochemistry and flow cytometry revealed low (22Rv1) and high (C4-2 and LNCaP) PSMA expression, and high, comparable AR positivity. Treatment with enzalutamide increased PSMA levels in 22Rv1, C4-2, and LNCaP (2.2/2.3/2.6-fold, p = 0.0005/0.03/0.046) after one week compared to DMSO-treated controls as assessed by flow cytometry. NOD/Scid mice bearing 22Rv1 tumors were treated with enzalutamide for two weeks. Positron emission tomography/computed tomography (PET/CT) demonstrated higher tumor uptake of 68Ga-PSMA after enzalutamide treatment (p = 0.004). Similarly, a clinical case with low baseline PSMA avidity demonstrated increased uptake of 68Ga-PSMA after enzalutamide on PET/CT and post-therapeutic 177Lu-PSMA scintigraphy in a patient with mCRPC. Enzalutamide induced PSMA expression in the 22Rv1 xenograft model and in an mCRPC patient, both with low baseline tumoral PSMA levels. Therefore, enzalutamide pre-treatment might render patients with low PSMA expression eligible for 177Lu-PSMA RLT.
- 11 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (14) , 7431
Open AccessEnzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutamide on PSMA expression. Assessment of PSMA and androgen receptor (AR) expression on the human PC cell lines 22Rv1, C4-2, and LNCaP by immunohistochemistry and flow cytometry revealed low (22Rv1) and high (C4-2 and LNCaP) PSMA expression, and high, comparable AR positivity. Treatment with enzalutamide increased PSMA levels in 22Rv1, C4-2, and LNCaP (2.2/2.3/2.6-fold, p = 0.0005/0.03/0.046) after one week compared to DMSO-treated controls as assessed by flow cytometry. NOD/Scid mice bearing 22Rv1 tumors were treated with enzalutamide for two weeks. Positron emission tomography/computed tomography (PET/CT) demonstrated higher tumor uptake of 68Ga-PSMA after enzalutamide treatment (p = 0.004). Similarly, a clinical case with low baseline PSMA avidity demonstrated increased uptake of 68Ga-PSMA after enzalutamide on PET/CT and post-therapeutic 177Lu-PSMA scintigraphy in a patient with mCRPC. Enzalutamide induced PSMA expression in the 22Rv1 xenograft model and in an mCRPC patient, both with low baseline tumoral PSMA levels. Therefore, enzalutamide pre-treatment might render patients with low PSMA expression eligible for 177Lu-PSMA RLT.
- Open Access
- 1 May 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 96-97, 101-111
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
- 1 May 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 96-97, 101-111
Open AccessDrug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
- Open Access
- 16 March 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Increased longevity due to sexual activity in mole-rats is associated with transcriptional changes in the HPA stress axis
Sexual activity and/or reproduction are associated with a doubling of life expectancy in the long-lived rodent genusFukomys. To investigate the molecular mechanisms underlying this phenomenon, we analyzed 636 RNA-seq samples across 15 tissues. This analysis suggests that changes in the regulation of the hypothalamic–pituitary–adrenal stress axis play a key role regarding the extended life expectancy of reproductive vs. non-reproductive mole-rats. This is substantiated by a corpus of independent evidence. In accordance with previous studies, the up-regulation of the proteasome and so-called ‘anti-aging molecules’, for example, dehydroepiandrosterone, is linked with enhanced lifespan. On the other hand, several of our results are not consistent with knowledge about aging of short-lived model organisms. For example, we found the up-regulation of the insulin-like growth factor 1/growth hormone axis and several other anabolic processes to be compatible with a considerable lifespan prolongation. These contradictions question the extent to which findings from short-lived species can be transferred to longer-lived ones.
- 16 March 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Open AccessIncreased longevity due to sexual activity in mole-rats is associated with transcriptional changes in the HPA stress axis
Sexual activity and/or reproduction are associated with a doubling of life expectancy in the long-lived rodent genusFukomys. To investigate the molecular mechanisms underlying this phenomenon, we analyzed 636 RNA-seq samples across 15 tissues. This analysis suggests that changes in the regulation of the hypothalamic–pituitary–adrenal stress axis play a key role regarding the extended life expectancy of reproductive vs. non-reproductive mole-rats. This is substantiated by a corpus of independent evidence. In accordance with previous studies, the up-regulation of the proteasome and so-called ‘anti-aging molecules’, for example, dehydroepiandrosterone, is linked with enhanced lifespan. On the other hand, several of our results are not consistent with knowledge about aging of short-lived model organisms. For example, we found the up-regulation of the insulin-like growth factor 1/growth hormone axis and several other anabolic processes to be compatible with a considerable lifespan prolongation. These contradictions question the extent to which findings from short-lived species can be transferred to longer-lived ones.
- Open Access
- 19 February 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (2) , 212
Imaging Inflammation with Positron Emission Tomography
The impact of inflammation on the outcome of many medical conditions such as cardiovascular diseases, neurological disorders, infections, cancer, and autoimmune diseases has been widely acknowledged. However, in contrast to neurological, oncologic, and cardiovascular disorders, imaging plays a minor role in research and management of inflammation. Imaging can provide insights into individual and temporospatial biology and grade of inflammation which can be of diagnostic, therapeutic, and prognostic value. There is therefore an urgent need to evaluate and understand current approaches and potential applications for imaging of inflammation. This review discusses radiotracers for positron emission tomography (PET) that have been used to image inflammation in cardiovascular diseases and other inflammatory conditions with a special emphasis on radiotracers that have already been successfully applied in clinical settings.
- 19 February 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (2) , 212
Open AccessImaging Inflammation with Positron Emission Tomography
The impact of inflammation on the outcome of many medical conditions such as cardiovascular diseases, neurological disorders, infections, cancer, and autoimmune diseases has been widely acknowledged. However, in contrast to neurological, oncologic, and cardiovascular disorders, imaging plays a minor role in research and management of inflammation. Imaging can provide insights into individual and temporospatial biology and grade of inflammation which can be of diagnostic, therapeutic, and prognostic value. There is therefore an urgent need to evaluate and understand current approaches and potential applications for imaging of inflammation. This review discusses radiotracers for positron emission tomography (PET) that have been used to image inflammation in cardiovascular diseases and other inflammatory conditions with a special emphasis on radiotracers that have already been successfully applied in clinical settings.
- Open Access
The HPA stress axis shapes aging rates in long-lived, social mole-rats
Sexual activity and/or reproduction doubles life expectancy in the long-lived rodent genus Fukomys . To investigate the molecular mechanisms underlying this phenomenon, we analyzed a total of 636 RNA-seq samples across 15 tissues. This analysis suggests that the differences in life expectancy between reproductive and non-reproductive mole-rats are mainly caused by critical changes in the regulation of the hypothalamic-pituitary-adrenal stress axis, which we further substantiate with a series of independent evidence. In accordance with previous studies, the up-regulation of the proteasome and several so-called “anti-aging molecules”, such as DHEA, is also linked with enhanced life expectancy. On the other hand, several our results oppose crucial findings in short-lived model organisms. For example, we found the up-regulation of the IGF1/GH axis and several other anabolic processes to be compatible with a considerable lifespan prolongation. These contradictions question the extent to which findings from short-lived species can be transferred to longer-lived ones.
Open AccessThe HPA stress axis shapes aging rates in long-lived, social mole-rats
Sexual activity and/or reproduction doubles life expectancy in the long-lived rodent genus Fukomys . To investigate the molecular mechanisms underlying this phenomenon, we analyzed a total of 636 RNA-seq samples across 15 tissues. This analysis suggests that the differences in life expectancy between reproductive and non-reproductive mole-rats are mainly caused by critical changes in the regulation of the hypothalamic-pituitary-adrenal stress axis, which we further substantiate with a series of independent evidence. In accordance with previous studies, the up-regulation of the proteasome and several so-called “anti-aging molecules”, such as DHEA, is also linked with enhanced life expectancy. On the other hand, several our results oppose crucial findings in short-lived model organisms. For example, we found the up-regulation of the IGF1/GH axis and several other anabolic processes to be compatible with a considerable lifespan prolongation. These contradictions question the extent to which findings from short-lived species can be transferred to longer-lived ones.